Sensome Announces Successful Proof‑of‑Concept Adding Its Biological Intelligence to Robotic Thrombectomy

Sensome’s Clot‑Sensing Guidewire, Steered by Robocath’s Robotic Systems, Demonstrates Path Towards Physical AI

PARIS--(BUSINESS WIRE)--#cardiology--Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced successful Proof of Concept (POC) cases using its Clotild® Smart Guidewire System with commercial and next-generation robotic systems from Robocath, a global leader in robotic solutions dedicated to interventional cardiology, to access and characterize clot in cerebral blood vessels. The effort demonstrates the feasibility of using Sensome’s smart guidewire technology with any robotic system accessing the vasculature to provide valuable sensor-obtained biological intelligence that can enhance a procedure.

Today, physicians treating stroke must often take a time-consuming, trial-and-error approach to thrombectomy as available imaging is murky and provides little information about the occlusion they are treating. The Clotild clot-sensing guidewire integrates the world’s smallest electrical impedance sensor with predictive models and is designed to instantly identify clot composition and true clot position in situ to reduce guesswork and inform treatment approach during mechanical thrombectomy.

The proof-of-concept robotic procedures were performed using Sensome’s clot-sensing guidewire to navigate and sense tissue in the hands of Robocath’s R-ONE commercial robotic system and a next-generation robot under development in a silicone model of the brain with animal clot inserted to mimic a stroke. View the proof-of-concept case here.

“The prospect of using robotics and AI to improve safety and efficiency in minimally invasive neurovascular interventions, such as thrombectomy, is exciting to us as physicians as we look to optimize our outcomes. The technology also has the potential to expand access to thrombectomy to rural areas, where a local robot could perform thrombectomy driven by remote experts from high-volume centers,” said Raphaël Blanc, MD, Deputy Head of Interventional Neuroradiology at Adolphe de Rothschild Foundation Hospital, Paris, who performed the proof-of-concept cases. “Using the smart guidewire instead of a conventional guidewire provided me with seamless navigation and in situ clot information that I cannot get any other way. Combining robotics with better information through sensing may become the future of thrombectomy.”

“This experience shows us that our clot-sensing guidewire has the potential to become the guidewire of choice for any medical robotic system that steers a wire,” said Franz Bozsak, CEO and co-founder of Sensome. “By successfully combining our breakthrough sensor technology with robotics, we are taking an important step towards physical AI, where, over time, sensor‑derived data from clot and other tissue can feed our AI database to support easier and more precise device selection, positioning, and delivery.”

“We are excited to see that simply swapping to a smart wire with our robot can obtain procedural data with the potential to make robotic surgery even safer. A robot that can differentiate between clot and vessel wall and react accordingly has the potential to limit risk and optimize safety for any robotic thrombectomy,” said Philippe Bencteux, President and founder of Robocath. “Combining the intelligence from smart devices with our own robotic intelligence will ultimately enable us to provide a new level of precision and care for patients with acute ischemic stroke.”

ABOUT SENSOME

Sensome, a clinical-stage healthtech start-up, provides biological intelligence to physicians during minimally invasive procedures, bridging gaps left by conventional imaging. The company has developed a patented, breakthrough microsensor technology that combines the world's smallest impedance-based sensor with proprietary predictive algorithms to identify and characterize tissues in situ in real time. The technology has been studied in three clinical indications, including total occlusion characterization (ischemic stroke, peripheral vascular disease) and in-situ tool-in-lesion confirmation (lung cancer). The company intends to leverage its growing tissue database to deliver AI-driven insights to physicians, and eventually, to couple this data with robotics to create physical AI enabling increasingly autonomous robotic minimally invasive interventions. Sensome partners with leading medtech companies to design, manufacture and distribute smart medical devices powered by its biological intelligence, including leading guidewire manufacturer ASAHI INTECC for the Clotild Smart Guidewire System.

The Clotild Smart Guidewire System is considered an investigational device and is not approved for commercial use in the U.S or any other jurisdiction.

ABOUT ROBOCATH

Founded in 2009 by Philippe Bencteux, MD, Robocath is a global leader in vascular robotics based in Rouen, France. The company designs and markets advanced robotic solutions powered by a unique bionic technology for endovascular interventions, designed to integrate seamlessly with leading devices and cathlab workflows.

Its first commercial platform, R-One, dedicated to robotic-assisted coronary angioplasty—one of the most frequently performed procedures worldwide—has obtained CE Mark and NMPA certification and demonstrated a 98% technical procedural success rate with no MACE in multicenter clinical studies. R-One procedures are currently performed in Europe and China.

Robocath’s ambition is to expand robotic assistance across the endovascular field—including coronary, neurovascular and peripheral interventions—while accelerating innovation through artificial intelligence and enabling the future development of remote robotic procedures to broaden access to care.

MEDIA CONTACT:
Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
+1 310-902-1274